Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses

European Journal of Dermatology

Volumn 22, Issue 3, 2012, Pages 370-374

  Stockfleth, Eggert ^a   Zwingers, Thomas ^b   Willers, Christoph ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Fa Estimate GmbH Augsburg   (Germany)

^c Almirall Hermal GmbH   (Germany)

Author keywords

5 fluorouracil; Actinic keratoses; Diclofenac HA; Patient assessment; Recurrence rate; Salicylic acid

Indexed keywords

DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; PLACEBO; SALICYLIC ACID;

ACTINIC KERATOSIS; ADULT; AGED; APPLICATION SITE BURNING; APPLICATION SITE INFLAMMATION; APPLICATION SITE PRURITUS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SKIN EXAMINATION; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; RECURRENCE; SALICYLIC ACID; YOUNG ADULT;

EID: 84863219824     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1707     Document Type: Article

References (11)

1. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156(S3): 9-12.
2. Stockfleth E, Kerl H. Guidelines for management of actinic keratoses. Eur J Dermatol 2006; 16: 599-606.
3. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18(6): 1-10.
4. 5-fluorouracil 0.5%/salicylic acid 10.0% Summary of Product Characteristics. Almirall Hermal GmbH. 2011.
5. Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses - histological and clinical study results. Br J Dermatol 25 April 2011; DOI: 10.1111/j.1365-2133.2011.10387.x (Epub ahead of print).
6. European Medicines Agency: Reflection Paper On The Regulatory Guidance For The Use Of Health related Quality Of Life (Hrql) Measures In The Evaluation Of Medicinal Products, July 2005. http://www.emea.europa.eu/pdfs/human/ewp/13939104en.pdf.
7. US Department of Health and Human Services. Food and Drug Administration: Guidance for Industry. Patient reported outcome measures: Use in medical product development to support labeling claims, December 2009. http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM193282.pdf
8. Pathak MA, Fitzpatrick TB, Greiter F et al. In: Fitzpatrick TB, Eisen AZ, Wolff K et al., eds. Dermatology in General Medicine. 3rd ed. New York: McGraw-Hill Book Company, 1987: 1507-1522.
9. Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24:738-743.
10. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil versus cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(S2): 34-40.
11. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol 2006; 7(4): 231-236.